Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

por Patel, Hitisha K., Tao, Nianjun, Lee, Kyung-Min, Huerta, Mariela, Arlt, Heike, Mullarkey, Tara, Troy, Steven, Arteaga, Carlos L., Bihani, Teeru
Publicado 2019